2TK Stock Chart & Stats
€2.88
€0.04(1.27%)
At close: 4:00 PM EDT
€2.88
€0.04(1.27%)
Day’s Range― - ―
52-Week Range€1.17 - €3.70
Previous CloseN/A
Volume0.00
Average Volume (3M)86.00
Market Cap
€179.73M
Enterprise Value€398.44M
Total Cash (Recent Filing)€88.76M
Total Debt (Recent Filing)€467.00K
Price to Earnings (P/E)―
Beta0.86
Next Earnings
Nov 18, 2026EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.99
Shares Outstanding81,261,154
10 Day Avg. Volume0
30 Day Avg. Volume86
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)1.52
Price to Sales (P/S)0.00
P/FCF Ratio-1.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€8.45Price Target Upside193.49% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.81
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Very Low LeverageMinimal debt reduces solvency risk and avoids a substantial interest burden while Eledon funds clinical development. This gives management greater flexibility to allocate capital toward tegoprubart and may provide more room to pursue financing or partnerships without an already heavily leveraged balance sheet.
Defined Therapeutic MechanismTegoprubart is built around a clearly defined immunology mechanism rather than an undifferentiated development approach. Targeting CD40 ligand is intended to address graft rejection and broad immunosuppression needs, giving the lead program a focused basis for clinical development.
Focused Transplant And Autoimmune PipelineEledon’s focus on transplantation and autoimmune diseases targets areas where immune modulation is central to patient outcomes. Concentrating resources on related immunology applications can support a coherent development strategy and create multiple potential uses for the company’s therapeutic approach.
Bears Say
No Reported RevenueEledon has not yet demonstrated commercial revenue, so its operations remain dependent on advancing development programs rather than product sales. Until a candidate is approved and commercialized, the company lacks recurring operating income to offset research spending or support internally funded growth.
Large And Worsening LossesDeep operating and net losses show that Eledon remains far from breakeven and that its current development model consumes substantial capital. The deterioration in TTM net income from 2025 increases the risk that future progress will require continued external funding before any product can generate revenue.
Persistent Cash Burn And Funding RiskOngoing negative operating and free cash flow means Eledon must continue using capital to fund operations, while the recent increase in cash burn can tighten its financial runway. Declining equity is consistent with sustained losses and raises the prospect of additional financing and dilution.
Eledon Pharmaceuticals News
2TK FAQ
What was Eledon Pharmaceuticals’s price range in the past 12 months?
Eledon Pharmaceuticals lowest stock price was €1.17 and its highest was €3.70 in the past 12 months.
What is Eledon Pharmaceuticals’s market cap?
Eledon Pharmaceuticals’s market cap is €179.73M.
When is Eledon Pharmaceuticals’s upcoming earnings report date?
Eledon Pharmaceuticals’s upcoming earnings report date is Nov 18, 2026 which is in 36 days.
How were Eledon Pharmaceuticals’s earnings last quarter?
Eledon Pharmaceuticals released its earnings results on Aug 13, 2026. The company reported -€0.242 earnings per share for the quarter, missing the consensus estimate of -€0.141 by -€0.1.
Is Eledon Pharmaceuticals overvalued?
According to Wall Street analysts Eledon Pharmaceuticals’s price is currently Undervalued.
Does Eledon Pharmaceuticals pay dividends?
Eledon Pharmaceuticals does not currently pay dividends.
What is Eledon Pharmaceuticals’s EPS estimate?
Eledon Pharmaceuticals’s EPS estimate is -0.17.
How many shares outstanding does Eledon Pharmaceuticals have?
Eledon Pharmaceuticals has 81,261,154 shares outstanding.
What happened to Eledon Pharmaceuticals’s price movement after its last earnings report?
Eledon Pharmaceuticals reported an EPS of -€0.242 in its last earnings report, missing expectations of -€0.141. Following the earnings report the stock price went down -1.887%.
Which hedge fund is a major shareholder of Eledon Pharmaceuticals?
Currently, no hedge funds are holding shares in DE:2TK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Eledon Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€8.45 (193.49% Upside)
€8.45 (193.49% Upside)
Blogger Sentiment
Bullish
DE:2TK Sentiment 100%
Sector Average 66%
Sector Average 66%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-10.94%
12-Months-Change
Fundamentals
Return on Equity
-136.45%
Trailing 12-Months
Asset Growth
-12.98%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Eledon Pharmaceuticals
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating innovative treatments for individuals battling autoimmune disorders, amyotrophic lateral sclerosis (ALS), and those undergoing organ or cell transplantation. Their flagship therapeutic candidate, AT-1501, is a humanized monoclonal antibody engineered to specifically target CD40 Ligand, a crucial protein found on the surface of immune system T cells. This compound is currently undergoing Phase 2a clinical studies for ALS treatment and Phase 2 trials for islet cell transplantation, aiming to address type 1 diabetes. Previously known as Novus Therapeutics, Inc., the company adopted its current name, Eledon Pharmaceuticals, Inc., in January 2021. Its corporate headquarters are located in Irvine, California.
2TK Stock 12 Month Forecast
Average Price Target
€8.45
▲(193.49% Upside)
Technical Analysis
MacroGenics
―
Fate Therapeutics
―
ProQR
―
Bicycle Therapeutics
―
SAB Biotherapeutics
―